Suppr超能文献

低收入和中等收入国家不适当使用抗生素的驱动因素。

Drivers of inappropriate antibiotic use in low- and middle-income countries.

作者信息

Otaigbe Idemudia Imonikhe, Elikwu Charles John

机构信息

Department of Medical Microbiology, School of Basic Clinical Sciences, Benjamin Carson (Snr.) College of Health & Medical Sciences, Babcock University, Ilishan Remo, Ogun State, Nigeria.

出版信息

JAC Antimicrob Resist. 2023 May 31;5(3):dlad062. doi: 10.1093/jacamr/dlad062. eCollection 2023 Jun.

Abstract

Antimicrobial resistance (AMR) is a global security threat that accounts for about 700 000 deaths annually. Studies have shown that antimicrobial resistance could result in a 2% to 3.5% reduction in global Gross Domestic Product by 2050 and a loss of between 60 and 100 trillion US dollars, worth of economic output resulting in significant and widespread human suffering. Low- and middle-income countries (LMICs) will be worse hit by an unchecked rise of AMR. For example, it is predicted that AMR could kill about 4.1 million people in Africa by 2050 if it is not curbed. Similarly rising rates of AMR will lead to increased treatment costs and an inability to attain universal health coverage, in LMICs with fragile health systems. Sadly, AMR is driven by the inappropriate use of antimicrobials, especially antibiotics. Inappropriate antibiotic use is a pertinent problem in LMICs where regulatory frame works are weak. Inappropriate antibiotic use in LMICs is a multifaceted problem that cuts across clinical and veterinary medicine and agriculture. Therefore, efforts geared at curbing inappropriate antibiotic use in LMICs must identify the factors that drive this problem (i.e. inappropriate antibiotic use) in these countries. A clear knowledge of these factors will guide effective policy and decision making to curb inappropriate antibiotic use and ultimately AMR. The focus of this review is to discuss the factors that drive inappropriate antibiotic use in LMICs.

摘要

抗菌药物耐药性(AMR)是一种全球安全威胁,每年导致约70万人死亡。研究表明,到2050年,抗菌药物耐药性可能导致全球国内生产总值下降2%至3.5%,经济产出损失60至100万亿美元,造成重大且广泛的人类痛苦。中低收入国家(LMICs)将受到AMR不受控制的上升的更严重打击。例如,据预测,如果不加以遏制,到2050年AMR可能在非洲导致约410万人死亡。同样,在卫生系统脆弱的中低收入国家,AMR发生率的上升将导致治疗成本增加,无法实现全民健康覆盖。可悲的是,AMR是由抗菌药物,尤其是抗生素的不当使用所驱动。在监管框架薄弱的中低收入国家,抗生素的不当使用是一个相关问题。中低收入国家抗生素的不当使用是一个多方面的问题,涉及临床医学、兽医学和农业。因此,旨在遏制中低收入国家抗生素不当使用的努力必须找出这些国家中导致这一问题(即抗生素不当使用)的因素。清楚了解这些因素将指导制定有效的政策和决策,以遏制抗生素的不当使用,并最终遏制AMR。本综述的重点是讨论导致中低收入国家抗生素不当使用的因素。

相似文献

1
Drivers of inappropriate antibiotic use in low- and middle-income countries.
JAC Antimicrob Resist. 2023 May 31;5(3):dlad062. doi: 10.1093/jacamr/dlad062. eCollection 2023 Jun.
3
4
Antimicrobial resistance in low- and middle-income countries: current status and future directions.
Expert Rev Anti Infect Ther. 2022 Feb;20(2):147-160. doi: 10.1080/14787210.2021.1951705. Epub 2021 Jul 19.
7
Antibiotic Use in Low and Middle-Income Countries and the Challenges of Antimicrobial Resistance in Surgery.
Antibiotics (Basel). 2020 Aug 9;9(8):497. doi: 10.3390/antibiotics9080497.
8
Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.
Antimicrob Resist Infect Control. 2018 Aug 9;7:98. doi: 10.1186/s13756-018-0384-3. eCollection 2018.
9
Differential Drivers of Antimicrobial Resistance across the World.
Acc Chem Res. 2019 Apr 16;52(4):916-924. doi: 10.1021/acs.accounts.8b00643. Epub 2019 Mar 8.

引用本文的文献

5
Environmental and Maternal Imprints on Infant Gut Metabolic Programming.
bioRxiv. 2025 Jul 24:2025.07.24.666662. doi: 10.1101/2025.07.24.666662.
6
Non-adherence to surgical antibiotic prophylaxis guidelines: findings from a mixed-methods study in a developing country.
Antimicrob Resist Infect Control. 2025 Jul 15;14(1):89. doi: 10.1186/s13756-025-01607-5.
9
Strengthening antimicrobial stewardship in public health facilities in Malawi through a participatory epidemiology approach.
JAC Antimicrob Resist. 2025 Jun 11;7(3):dlaf103. doi: 10.1093/jacamr/dlaf103. eCollection 2025 Jun.
10
Antibiotic use without prescription among children aged under 5 years in low- and middle-income countries: a systematic review and meta-analysis.
JAC Antimicrob Resist. 2025 Jun 6;7(3):dlaf093. doi: 10.1093/jacamr/dlaf093. eCollection 2025 Jun.

本文引用的文献

1
Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020-2022.
EClinicalMedicine. 2023 Mar;57:101848. doi: 10.1016/j.eclinm.2023.101848. Epub 2023 Feb 6.
2
Exploring the economic impact of inappropriate antibiotic use: the case of upper respiratory tract infections in Ghana.
Antimicrob Resist Infect Control. 2022 Apr 1;11(1):53. doi: 10.1186/s13756-022-01096-w.
3
Towards a fiercely urgent expansion of laboratory medicine in Africa.
Afr J Lab Med. 2021 Dec 17;10(1):1785. doi: 10.4102/ajlm.v10i1.1785. eCollection 2021.
4
Antimicrobial Use and Resistance in Agriculture and Food Production Systems in Africa: A Systematic Review.
Antibiotics (Basel). 2021 Aug 13;10(8):976. doi: 10.3390/antibiotics10080976.
5
Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit.
JAC Antimicrob Resist. 2019 Nov 12;1(3):dlz072. doi: 10.1093/jacamr/dlz072. eCollection 2019 Dec.
10
COVID-19 pandemic and antimicrobial resistance: Another call to strengthen laboratory diagnostic capacity in Africa.
Afr J Lab Med. 2020 Sep 23;9(1):1302. doi: 10.4102/ajlm.v9i1.1302. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验